{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"13","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"The estimates of incidence rates will be presented with corresponding 95% confidence intervals using the exact method.","dispersionType":"95% Confidence Interval","groups":[{"description":"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 60 minutes on days -11 to -8 and busulfan IV over 3 hours on days -10 to -9. Patients undergo TBI on day -6. Patients also receive cyclophosphamide IV over 2 hours on days -3 and -2.\n\nTRANSPLANTATION: Patients undergo DLI on day -6 and CD-34+ allogeneic PBSCT on day 0.\n\nGVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV or PO with taper beginning on day 42. Patients also receive mycophenolate mofetil IV BID on days -1 to 28.\n\nFludarabine: Given IV\n\nBusulfan: Given IV\n\nTotal Body Irradiation (TBI): 2 Gy administered as part of the conditioning regimen\n\nDonor Lymphocyte Infusion (DLI): Undergo DLI\n\nCyclophosphamide (CY): Given IV\n\nTacrolimus: Given IV or PO\n\nMycophenolate mofetil: Given IV\n\nAllogeneic hematopoietic stem cell transplantation: Undergo CD34+ allogeneic PBSCT\n\nPeripheral blood stem cell transplantation (PBSCT): Undergo CD34+ allogeneic PBSCT","id":"OG000","title":"Treatment (Allogeneic PBSCT)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"At 100 days","title":"Incidence of Treatment Related Mortality (TRM)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}